HT
LJPC

HAP Trading’s La Jolla Pharmaceutical Company LJPC Stock Holding History

HAP Trading’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-36,636
Closed -$1.09M – 1254
2018
Q1 		$1.09M Buy
+36,636
New +$1.18M 0.05% 211
2017
Q4 		– Sell
-75,222
Closed -$2.62M – 1278
2017
Q3 		$2.62M Buy
+75,222
New +$2.42M 0.12% 145

Other funds holding LJPC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

HAP Trading's LJPC Position: Q2 2018 in Review

HAP Trading sold out of La Jolla Pharmaceutical Company (LJPC) in Q2 2018, closing a stake of 36,636 shares — an estimated $1.09M sold.

HAP Trading first reported a position in LJPC in Q3 2017 and held it in 2 quarters. The position peaked at $2.62M in Q3 2017. 95 funds tracked by Wall St. Rank hold LJPC as of Q2 2018.

  • HAP Trading reported no remaining La Jolla Pharmaceutical Company position as of Q2 2018 after selling out during the quarter.
  • HAP Trading sold 36,636 La Jolla Pharmaceutical Company shares in Q2 2018, an estimated $1.09M.
  • HAP Trading first reported a position in La Jolla Pharmaceutical Company in Q3 2017 and held it in 2 quarters.
  • HAP Trading's La Jolla Pharmaceutical Company position peaked at $2.62M in Q3 2017.
  • 95 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q2 2018.

Based on HAP Trading's 13F filing for Q2 2018, filed 13 Aug 2018.